Streetbeat News

Analyst Ratings

ABBV

AVGO

DE

CNBC's Halftime Report discussed final trades, highlighting AbbVie, Deere & Company, and Broadcom as stocks to watch.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 5:00 pm

NIO

Morgan Stanley analyst Tim Hsiao reiterated an Overweight rating on NIO (NYSE:NIO) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 4:55 pm

BILL

INTU

Morgan Stanley analyst Jonathan Lee downgraded BILL Holdings from Overweight to Equal Weight, citing structural limitations, increased competition from Intuit, and macroeconomic pressure on total payment volume. The price target remains unchanged at $105.

Portfolio Pulse from Priya Nigam

June 12, 2023 | 4:53 pm

LBRT

OIH

OII

PUMP

RES

WHD

Oil prices tumble amid concerns of a potential production war between Russia and Saudi Arabia, and sluggish Chinese demand recovery. Goldman Sachs revises its December 2023 Brent forecast downward from $95 to $86 per barrel. Oil services stocks, such as WHD, LBRT, RES, OII, and PUMP, outperform oil E&Ps.

Portfolio Pulse from Piero Cingari

June 12, 2023 | 4:51 pm

PLUG

Plug Power shares are trading higher following the announcement of its ambitious targets ahead of its Analyst Day event. The company aims to achieve $1.4 billion in revenue by 2023 and annual sales of $20 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 4:51 pm

COGT

Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Cogent Biosciences (NASDAQ:COGT) and keeps the $22 price target.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 4:45 pm

GS

XOM

Goldman Sachs Group cut its oil price forecast for the third time in six months, affecting oil investors. Despite this, hedge funds are increasing bets on Brent and WTI crude. Exxon Mobil Corp (NYSE:XOM) shares opened 1.21% lower but are rebounding, offering investors upside opportunity for equity and dividend gains.

Portfolio Pulse from AJ Fabino

June 12, 2023 | 4:45 pm

KDNY

Cantor Fitzgerald analyst Charles Robertson II downgraded Chinook Therapeutics (NASDAQ:KDNY) from Overweight to Neutral and announced a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 4:43 pm

KDNY

William Blair analyst Matt Phipps downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 4:41 pm

CVNA

Citigroup analyst Ronald Josey maintains a Neutral rating on Carvana (NYSE:CVNA) and raises the price target from $11 to $25.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 4:33 pm